Commercial Medicines Unit

Contract awards

• Strategic stockpile of medicines 2017

  Location: United Kingdom

  Awarded contractPublished 18 Jan, 2019Source Contracts Finder archive

  This procurement exercise has established a framework agreement which Public Health England will call-off their requirements for the stockpile of emergency medicines.

  Awarded to Actavis UK Ltd, Accord Healthcare Ltd, Bayer Plc, Bowmed Ibisqus Ltd, Kent Pharmaceuticals Ltd, Sigma Pharmaceuticals Plc, Wockhardt UK Ltd

• Invitation to offer for NHS National Framework Agreement for the supply of Human Albumin and Human Anti-D Immunoglobulin

  Location: United Kingdom

  Awarded contractPublished 17 Aug, 2018Value £21.14mSource Contracts Finder archive

  Invitation to offer for an NHS National Framework Agreement for the supply of Human Albumin and Human Anti-D Immunoglobulin. The period of the framework agreement will be 01.04.17 - 31.03.18 with options to extend for up to a further 36 months. Please refer to Document No.05 for a list of purchasing points.

  Awarded to see attached

• NHS National Framework Agreement for the supply of Nitric Oxide Therapy. To include the supply of gas, rental of cylinders and delivery equipment, maintenance and consumables

  Location: United Kingdom

  Awarded contractPublished 17 Aug, 2018Value £15.00mSource Contracts Finder archive

  NHS National framework agreement for the supply of Nitric Oxide Therapy. To include the supply of gas, rental of cylinders and delivery equipment, maintenance and consumables. The framework will commence on 1st April 2016 for a period of 2 years until 31st March 2018, with options to extend for up to a further 24 mont

  Awarded to Please refer to spreadsheet called "Awarded suppliers name, post

• NHS National Framework Agreement for the supply of Recombinant Factor IX products for the treatment of bleeding disorders

  Location: United Kingdom

  Awarded contractPublished 17 Aug, 2018Value £41.00mSource Contracts Finder archive

  The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Wales, Scotland and Northern Ireland. The framework may also be used by private sector contractors and agents working on behalf of the above. Please refer to Document 05d in the ITO documents for the l

  Awarded to Please refer to the document "Parties appointed to the framework

• NHS National Framework Agreement for the supply of Human Cell Line Recombinant Factor VIII products

  Location: United Kingdom

  Awarded contractPublished 17 Aug, 2018Value £3.75mSource Contracts Finder archive

  NHS National framework agreement for the supply of Human Cell Line Recombinant Factor VIII products. The framework will commence on 1st July 2016 to 31st March 2017, with options to extend for up to a further 39 months. Please refer to the ITO, Document No.05d for a list of Participating Authorities. Additional inform

  Awarded to Please refer to "Parties appointed to the framework agreement"

• National Framework Agreement for the Supply of Immunoglobulin

  Location: United Kingdom

  Awarded contractPublished 17 Aug, 2018Value £187.35mSource Contracts Finder archive

  National Framework Agreement for the Supply of Immunoglobulin Offer reference number: CM/PHS/13/5404 Period of framework agreement: 1st July 2017 to 30th June 2018 with options to extend up to a further 36 months Additional information: National Framework Agreement for the Supply of Immunoglobulin Award Documents

  Awarded to Please refer to word doc called Awarded Suppliers Name

• Dynamic Purchasing System (DPS) for the supply of antibiotics and IV fluids

  Location: United Kingdom

  Awarded contractPublished 30 Nov, 2017Source Contracts Finder archive

  The establishment of a dynamic purchasing system (DPS) to allow for the purchase and stockpile of Antibiotics and IV Fluids for the treatment of influenza related secondary bacterial infections. Note that the DPS arrangement shall be valid for a period of 10 years.The Contracting Authority intends to use the Dynamic P

  Awarded to B Braun Medical Ltd, Fresenius Kabi Ltd, GlaxoSmithKline UK Ltd, Kent Pharmaceuticals Ltd, Sandoz Ltd

• NHS Framework Agreement for Hepatitis C Medicines for Midlands and East and North of England regions

  Location: United Kingdom

  Awarded contractPublished 24 Apr, 2017Value £85.00mSource Contracts Finder archive

  NHS framework agreement for Hepatitis C medicines for Midlands and East and North of England regions. Period of framework agreement: 1.3.2017 - 28.2.2018 with an option to extend for up to 12 months. Additional information: NHS framework agreement for Hepatitis C medicines for Midlands and East and North of England r

  Awarded to Please refer to award schedules for list of awarded suppliers

• NHS Framework Agreement for Branded Pharmaceuticals - North of England Tranche A.

  Location: United Kingdom

  Awarded contractPublished 24 Apr, 2017Value £575.68mSource Contracts Finder archive

  Branded North of England Branded Medicines - Tranche A - March 2017

  Awarded to Please refer to award schedules for awarded suppliers

• NHS Framework Agreement for the Midlands and East Pharmacy Purchasing Group for the supply of Proprietary Pharmaceuticals - Tranche B

  Location: United Kingdom

  Awarded contractPublished 24 Apr, 2017Value £204.76mSource Contracts Finder archive

  NHS Framework Agreement for the Midlands and East Pharmacy Purchasing Group for the supply of Proprietary Pharmaceuticals - Tranche B

  Awarded to please see award schedules for list of suppliers

• NHS Framework Agreement for Branded Pharmaceuticals – National

  Location: United Kingdom

  Awarded contractPublished 24 Apr, 2017Value £876.88mSource Contracts Finder archive

  NHS Framework Agreement for Branded Pharmaceuticals – National

  Awarded to please refer to award schedules

• NHS Pharmaceuticals Products Transition 2017_1

  Location: United Kingdom

  Awarded contractPublished 21 Apr, 2017Value £40.00mSource Contracts Finder archive

  NHS Pharmaceuticals 2017_1 Offer reference number: CM/PHG/15/5490 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months Potential periods of call-offs under the framework agreement: North West & Eastern & North London: 01/05/2017 to 31/01/2018 (9 months) Sou

  Awarded to See attachments for list of awarded suppliers

• Contract award – Commercial Medicines Unit

  Location: United Kingdom

  Awarded contractPublished 21 Apr, 2017Value €182.51MSource TED archive

  Awarded to For details of the awarded supplier, please see section VI.2

• Contract award – Commercial Medicines Unit

  Location: United Kingdom

  Awarded contractPublished 21 Apr, 2017Value €2.00BSource TED archive

  Awarded to For details of the awarded supplier, please see section VI.3

• Contract award – Commercial Medicines Unit

  Location: United Kingdom

  Awarded contractPublished 21 Apr, 2017Value €228.49MSource TED archive

  Awarded to For details of the awarded supplier, please see section VI.2

• Contract award – Commercial Medicines Unit

  Location: United Kingdom

  Awarded contractPublished 21 Apr, 2017Value €467.13MSource TED archive

  Awarded to For details of the awarded supplier, please see section VI.2)

• NHS Pharmaceuticals 2016_2

  Location: United Kingdom

  Awarded contractPublished 9 Mar, 2017Value £68.80mSource Contracts Finder archive

  Invitation to offer for NHS Pharmaceuticals 2016_2 Offer reference number: CM/PHG/12/5379 Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 36 months Potential periods of call-offs under the framework agreement: North West & Eastern & North London: 01/01/2017 to 31/

  Awarded to Please see attachments for awarded suppliers, Please see attachments

• NHS Pharmaceutical Products

  Location: United Kingdom

  Awarded contractPublished 31 Jan, 2017Value £155.00mSource Contracts Finder archive

  NHS Pharmaceutical Products: Reference number: CM/PHG/15/5467. Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 48 months. Potential periods of call-offs under the framework agreement: Oral Products (100 %); All Regions: 1.3.2017 to 28.2.2019 (24 months). Hospital onl

  Awarded to See attachments for list of awarded suppliers

• Contract for the supply of BCG vaccine

  Location: United Kingdom

  Awarded contractPublished 9 Jan, 2017Source Contracts Finder archive

  The provision of a vaccine to protect against tuberculosis, to be used in the national immunisation programme.

  Awarded to Intervax Ltd

• Contract for the supply of rotavirus vaccine

  Location: United Kingdom

  Awarded contractPublished 22 Dec, 2016Source Contracts Finder archive

  The provision of rotavirus vaccine to be used as part of the national childhood immunisation programme, deliveries will be required from 1 June 2017 to 31 May 2019, with an option to extend for up to an additional 24 months

  Awarded to GlaxoSmithKline UK Ltd